Aurinia Announces Management Change And Grant Of Stock Options

Published: Feb 19, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VICTORIA, British Columbia, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals Inc. (TSX-V:AUP) ("Aurinia" or the "Company") today announced that Dr. Robert Foster has decided to resign from his current position as Chief Scientific Officer, effective immediately, in order to pursue other opportunities. To help facilitate the continued development of its lead product, voclosporin, as an important new therapy for lupus nepthritis, Dr. Foster has agreed to remain available to consult with the Company on an as-needed basis.

Help employers find you! Check out all the jobs and post your resume.

Back to news